ZA200201923B - Viral replicons and viruses dependent on inducing agents. - Google Patents
Viral replicons and viruses dependent on inducing agents. Download PDFInfo
- Publication number
- ZA200201923B ZA200201923B ZA200201923A ZA200201923A ZA200201923B ZA 200201923 B ZA200201923 B ZA 200201923B ZA 200201923 A ZA200201923 A ZA 200201923A ZA 200201923 A ZA200201923 A ZA 200201923A ZA 200201923 B ZA200201923 B ZA 200201923B
- Authority
- ZA
- South Africa
- Prior art keywords
- replicon
- virus
- replication
- hiv
- rtta
- Prior art date
Links
- 230000001939 inductive effect Effects 0.000 title claims abstract description 55
- 230000003612 virological effect Effects 0.000 title claims abstract description 34
- 241000700605 Viruses Species 0.000 title claims description 117
- 230000001419 dependent effect Effects 0.000 title claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 38
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 27
- 230000002238 attenuated effect Effects 0.000 claims abstract description 23
- 108010057466 NF-kappa B Proteins 0.000 claims abstract description 9
- 102000003945 NF-kappa B Human genes 0.000 claims abstract description 9
- 230000010076 replication Effects 0.000 claims description 68
- 101150024821 tetO gene Proteins 0.000 claims description 38
- 229960005486 vaccine Drugs 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 29
- 230000029812 viral genome replication Effects 0.000 claims description 23
- 101710149951 Protein Tat Proteins 0.000 claims description 22
- 239000012190 activator Substances 0.000 claims description 22
- 208000015181 infectious disease Diseases 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 108700004028 nef Genes Proteins 0.000 claims description 10
- 101150023385 nef gene Proteins 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 9
- 230000037431 insertion Effects 0.000 claims description 9
- 208000030507 AIDS Diseases 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 2
- JBIWCJUYHHGXTC-AKNGSSGZSA-N doxycycline Chemical compound O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O JBIWCJUYHHGXTC-AKNGSSGZSA-N 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 43
- 230000014509 gene expression Effects 0.000 abstract description 31
- 230000001105 regulatory effect Effects 0.000 abstract description 15
- 230000001976 improved effect Effects 0.000 abstract description 8
- 230000002068 genetic effect Effects 0.000 abstract description 6
- 108700004027 tat Genes Proteins 0.000 abstract description 5
- 101150098170 tat gene Proteins 0.000 abstract description 5
- 229940124590 live attenuated vaccine Drugs 0.000 abstract description 3
- 229940023012 live-attenuated vaccine Drugs 0.000 abstract description 3
- 229940033332 HIV-1 vaccine Drugs 0.000 abstract description 2
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 42
- 208000031886 HIV Infections Diseases 0.000 description 39
- 238000012217 deletion Methods 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 230000037430 deletion Effects 0.000 description 17
- 241000713311 Simian immunodeficiency virus Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 238000011144 upstream manufacturing Methods 0.000 description 10
- 108700039887 Essential Genes Proteins 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000003362 replicative effect Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 230000001042 autoregulative effect Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 238000010839 reverse transcription Methods 0.000 description 7
- 230000002269 spontaneous effect Effects 0.000 description 7
- 230000002103 transcriptional effect Effects 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 229960003722 doxycycline Drugs 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 230000035892 strand transfer Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 241000282553 Macaca Species 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000007813 immunodeficiency Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 229940124718 AIDS vaccine Drugs 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101710149136 Protein Vpr Proteins 0.000 description 2
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000014493 regulation of gene expression Effects 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 229960001852 saquinavir Drugs 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000002435 Cyclin T Human genes 0.000 description 1
- 108010068106 Cyclin T Proteins 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010074124 Escherichia coli Proteins Proteins 0.000 description 1
- 241001197893 Glyptemys herpesvirus Species 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 108700010908 HIV-1 proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710192141 Protein Nef Proteins 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 102220470387 Thymosin beta-10_Y26A_mutation Human genes 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 102220002645 rs104894309 Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99202971A EP1083230A1 (de) | 1999-09-10 | 1999-09-10 | Virale Replikons und von induzierenden Wirkstoffen abhängige Viren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200201923B true ZA200201923B (en) | 2003-09-23 |
Family
ID=8240635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200201923A ZA200201923B (en) | 1999-09-10 | 2002-03-07 | Viral replicons and viruses dependent on inducing agents. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20030099613A1 (de) |
| EP (2) | EP1083230A1 (de) |
| JP (1) | JP2003509059A (de) |
| AT (1) | ATE428792T1 (de) |
| AU (1) | AU780984B2 (de) |
| CA (1) | CA2386530A1 (de) |
| DE (1) | DE60042026D1 (de) |
| WO (1) | WO2001020013A2 (de) |
| ZA (1) | ZA200201923B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1479774A1 (de) * | 2003-05-20 | 2004-11-24 | Academisch Medisch Centrum | Viren die induzierende Wirkstoffe für den Zelleintritt benötigen |
| EP1627563A1 (de) | 2004-08-10 | 2006-02-22 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Verfahren und Mittel zur Herstellung einer stabilisierten Zelle |
| US8383364B2 (en) | 2005-11-17 | 2013-02-26 | Tet Systems Gmbh & Co. Kg | Inducible expression systems |
| USRE49583E1 (en) | 2005-11-17 | 2023-07-18 | Tet Systems Gmbh & Co. Kg | Inducible expression systems |
| CA2633157C (en) | 2005-12-09 | 2018-10-09 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of antibody producing cells |
| WO2007067032A1 (en) | 2005-12-09 | 2007-06-14 | Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| EP2454283B1 (de) | 2009-07-15 | 2018-03-14 | AIMM Therapeutics B.V. | Mitteln und verfahren zur produktion von antikörper mit hohe affinität |
| EP2319918B1 (de) * | 2009-11-10 | 2013-01-16 | Centre National De La Recherche Scientifique | Vektor auf Lentivirus beruhend und dessen Verwendung bei der zielgerichteten Evolution von genomischen Regionen, Genen und Polynukleotiden |
| NZ611600A (en) | 2010-12-02 | 2015-02-27 | Aimm Therapeutics Bv | Means and methods for producing high affinity antibodies |
| DK3099709T3 (da) | 2014-01-31 | 2020-02-03 | Aimm Therapeutics Bv | Midler og fremgangsmåder til fremstilling af stabile antistoffer |
| CN111521359A (zh) * | 2020-04-29 | 2020-08-11 | 河南工程学院 | 面向结构振动主动控制优化配置方法及振动控制实验平台 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4100594A1 (de) * | 1991-01-08 | 1992-07-09 | Inst Genbiologische Forschung | Neue plasmide zur zeitlichen und oertlichen kontrollierten expression eines heterologen produktes in pflanzen |
| JP3881689B2 (ja) * | 1992-03-11 | 2007-02-14 | パウダージェクト ヴァクシンズ，インコーポレイテッド | 免疫不全ウイルス用の遺伝子ワクチン |
| US5723765A (en) * | 1994-08-01 | 1998-03-03 | Delta And Pine Land Co. | Control of plant gene expression |
| FR2735789B1 (fr) * | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
| US5965440A (en) * | 1995-12-07 | 1999-10-12 | The General Hospital Corporation | Controlled gene product delivery from a regulatable retroviral vector |
| WO1997048277A1 (en) * | 1996-06-20 | 1997-12-24 | The Salk Institute For Biological Studies | Modular assembly retroviral vectors and uses thereof |
| GB9621680D0 (en) * | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
| WO1998037185A2 (en) * | 1997-02-20 | 1998-08-27 | The Board Of Regents Of The University Of Texas System | Vectors for controlled gene expression |
| US5972650A (en) * | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
| US6121021A (en) * | 1997-12-16 | 2000-09-19 | Connaught Laboratories Limited | Constitutive expression of non-infectious HIV-like particles |
| JP4642239B2 (ja) * | 1998-12-22 | 2011-03-02 | ダウ・アグロサイエンス・エル・エル・シー | 作物植物での異系交雑および望ましくない遺伝子拡散を制限するための方法および遺伝子組成物 |
| EP1203088B1 (de) * | 1999-07-28 | 2005-03-30 | Stephen Smith | Konditionell kontrollierter, attenuierter hiv-1 impfstoff |
-
1999
- 1999-09-10 EP EP99202971A patent/EP1083230A1/de not_active Withdrawn
-
2000
- 2000-09-08 AU AU74595/00A patent/AU780984B2/en not_active Ceased
- 2000-09-08 EP EP00963145A patent/EP1212446B1/de not_active Expired - Lifetime
- 2000-09-08 DE DE60042026T patent/DE60042026D1/de not_active Expired - Fee Related
- 2000-09-08 JP JP2001523784A patent/JP2003509059A/ja active Pending
- 2000-09-08 WO PCT/NL2000/000637 patent/WO2001020013A2/en active IP Right Grant
- 2000-09-08 CA CA002386530A patent/CA2386530A1/en not_active Abandoned
- 2000-09-08 AT AT00963145T patent/ATE428792T1/de not_active IP Right Cessation
-
2002
- 2002-03-07 ZA ZA200201923A patent/ZA200201923B/en unknown
- 2002-03-08 US US10/097,542 patent/US20030099613A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001020013A2 (en) | 2001-03-22 |
| EP1083230A1 (de) | 2001-03-14 |
| EP1212446A2 (de) | 2002-06-12 |
| AU7459500A (en) | 2001-04-17 |
| JP2003509059A (ja) | 2003-03-11 |
| AU780984B2 (en) | 2005-04-28 |
| US20030099613A1 (en) | 2003-05-29 |
| DE60042026D1 (de) | 2009-05-28 |
| CA2386530A1 (en) | 2001-03-22 |
| EP1212446B1 (de) | 2009-04-15 |
| WO2001020013A3 (en) | 2001-09-27 |
| ATE428792T1 (de) | 2009-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Verhoef et al. | Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat | |
| Desrosiers | HIV with multiple gene deletions as a live attenuated vaccine for AIDS | |
| Shibata et al. | Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus | |
| EP1954811B1 (de) | Induzierbare expressionssysteme | |
| AU780984B2 (en) | Viral replicons and viruses dependent on inducing agents | |
| US6541003B1 (en) | Conditionally controlled, attenuated HIV vaccine | |
| Das et al. | A conditionally replicating virus as a novel approach toward an HIV vaccine | |
| CA2330618C (en) | Viral chimeras comprised of caev and hiv-1 genetic elements | |
| US20080234215A1 (en) | DNA composition and uses thereof | |
| USRE49583E1 (en) | Inducible expression systems | |
| Smith et al. | Constitutively dead, conditionally live HIV-1 genomes | |
| US5753490A (en) | Recombinant HIV and modified packaging cells and method for treating acquired immune deficiency syndrome | |
| US20030232060A1 (en) | Attenuated, doxycycline-inducible human immunodeficiency virus proviral molecular clones | |
| Centlivre et al. | A conditionally replicating human immunodeficiency virus in BRG-HIS mice | |
| US6063374A (en) | Recombinant HIV and modified packaging cells and method for using | |
| Christie | Immune Evasion and Viral Replication: Examining the Pressures that Influence the Evolution of CD8+ T-cell Epitope Sequences During HIV Infection | |
| Legrand et al. | A doxycycline-dependent HIV-1 replicates in vivo without inducing CD4+ T cell depletion | |
| WO2000018430A2 (en) | Live virus vaccines to protect primates from hiv-1 infection and disease |